Choose the language you would like to keep using on ACRO Medical.
We integrate clinical trial data and real-world evidence, using statistical comparison methods to evaluate a technology's relative value and competitiveness. We translate accumulated evidence into strategic decisions on technology assessment, R&D, investment, and business development.
Investment decisions should be evidence-based. ACRO helps sponsors and investors quantify an asset's market opportunity, competitive landscape, realistic clinical position, and market positioning, using evidence derived from primary data.
Biopharmaceutical investment decisions have become more cautious and analytical. Investors, business development teams, and portfolio committees increasingly require evidence-based answers to fundamental questions: How many patients are eligible? What is the competitive landscape? What are the realistic clinical and commercial opportunities?
Our value analyses combine primary data sources (KOSIS, NHIS, HIRA, KCCR, ClinicalTrials.gov, and EU CTR) and peer-reviewed literature with sponsors' strategic questions. The result is quantitative evidence ready for use in decision-making.